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Predialysis management of divalent ion metabolism. Disor- bone biopsy by the time they start dialysis [4]. Such
dered divalent ion metabolism has its origins in the earliest treatment is an important element of the ideal multidisci-
stages of renal impairment. Early intervention is essential to plinary approach to predialysis management as outlinedminimize its effects, especially in the light of recent reports
by Pereira [5] (Fig. 1).demonstrating an association between serum phosphate and
relative risk of mortality in dialysis patients. As the age and
comorbidity of patients accepted for renal replacement therapy
COMORBIDITY IN THE PREDIALYSISincreases, the complexity of their management also increases.
A dedicated “predialysis” enables a multidisciplinary team to POPULATION
intervene in an orderly and appropriate fashion to delay pro-
The number and age structure of the population ac-gression, modify comorbidity, prevent uraemic complications
cepted for renal replacement therapy has changed dra-and prepare the patient mentally and physically for dialysis
and renal transplantation. Part of this process involves the matically over the past 20 years [6, 7], so that those aged
identification of patients at high risk of the skeletal and bio- over 65 years now make up nearly 60% of new patients,
chemical complications of renal osteodystrophy. Correction of compared to less than 10% 20 years ago. Consequently,hypocalcemia, acidosis, hyperphosphatemia and rising PTH
these older patients bring with them an increased degreelevels should be achieved quickly. Oral calcitriol therapy is
of comorbidity, which manifests itself in the skeleton asfrequently necessary, and requires careful monitoring and su-
pervision. much as elsewhere (Table 1). Although osteoporosis is
not traditionally considered part of the syndrome of re-
nal osteodystrophy, it is likely to be present in a growing
The term “renal osteodystrophy” encompasses both proportion of the dialysis and transplant population. In
skeletal and extra-skeletal manifestations of disordered addition to the increasing age of new patients, many
divalent ion metabolism. Its origins are known to be in more have diabetes mellitus, either as their primary
the early stages of progressive renal impairment, when cause of renal failure or as an associated comorbid condi-
the glomerular filtration rate is as high as 60 ml/min [1, 2] tion. Diabetes and its complications—retinopathy, vas-
and serum creatinine may still be in the normal range. cular disease and neuropathy—can further contribute to
For example, a 70-year-old, 75 kg male with a serum decreased mobility and skeletal demineralization.
creatinine of 120 mm (1.4 mg/dl) has a creatinine clear- At least 50% of predialysis patients will subsequently
ance of around 52 ml/min. A 65 kg female of similar age die on renal replacement therapy from cardiovascular
would only have a clearance of 38 ml/min. or cerebrovascular causes, and it is now evident from
Although the significance of some of the skeletal le- the work of Block et al [3] that cardiovascular morbidity
sions is still controversial, the recently-reported associa- and mortality can probably be influenced by divalent ion
tion between serum phosphate and relative risk of mor- metabolism.
tality in dialysis patients [3] has given extra emphasis to
the importance of management of divalent ion metabo-
lism. Intuitively, one would expect that the earlier in the THE “PREDIALYSIS” CLINIC
course of progressive renal failure this control can be If all the elements of predialysis management are to
exerted, the better the outcome for the patient will be. be put in place against the background of an increasing
Therefore, monitoring and intervention should begin as number, age, and complexity of new patients, it is evident
soon as practically possible, since it is well known that that a dedicated and organized group of healthcare pro-
almost all patients have evidence of osteodystrophy on fessionals is required. It follows from this that such pa-
tients are most likely to experience all the elements of
predialysis management within the context of a specialistKey words: acidosis, dialysis, hypocalcemia, hyperphosphatemia, para-
thyroid hormone, renal osteodystrophy. predialysis clinic. The clinic’s motto should be “preven-
tion is better than cure,” especially since “cure” often is 1999 by the International Society of Nephrology
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Fig. 1. The multiple elements of predialysis man-
agement (Modified with permission from [5]).
Table 1. Factors resulting in skeletal comorbidity in already established on renal replacement therapy. The
an aging population
aims should be to correct hypocalcemia, acidosis, or
Age-related osteoporosis hyperphosphatemia, to monitor parathyroid hormone
Estrogen deficiency post menopause (PTH) levels, and to intervene with vitamin D3 analogsTestosterone deficiency
when necessaryOsteoarthritis
Immobility Hypocalcemia is a well-known, potent stimulus of
Corticosteroid therapy (either for primary renal disease or post- PTH secretion so that early and swift correction, aimingtransplant)
to bring serum calcium into the top half of the normalCyclosporine A therapy
range, is very important. This goal can generally be
achieved by oral calcium carbonate alone, which, if given
at meal times, has the additional benefit of reducing
not possible. Referral to the clinic should occur once a oral phosphate absorption. Tzukamoto demonstrated a
diagnosis of irreversible, progressive renal impairment greater than 50% reduction in serum PTH with introduc-
has been made and the GFR has declined to 30 ml/min. tion of calcium carbonate alone in patients with moder-
This corresponds to a serum creatinine of around 200 ate to severe renal impairment. On discontinuation of
mm (2.3 mg/dl) in a 75-kg male, or 160 mm (1.8 mg/dl) in the calcium, serum PTH rebounded significantly within
65 kg female. In view of the previous statement about six months [9]. Hypercalcemia is rarely a problem until
the origins of renal osteodystrophy [1, 2], it might seem residual renal function falls below a GFR of 10 ml/min.
appropriate to refer at an earlier stage, but such an ap- Acidosis promotes demineralization and potentiates
proach is not practical in most centers. Unfortunately,
the effect of PTH on bone and may also decrease
it is well known that between 20 and 40% of patients
calcitriol production [10]. In contrast, correction has
are not seen by a nephrologist before they reach the stage
been shown to slow progression of hyperparathyroidism
of requiring dialysis [8], and therefore no monitoring or
[11]. This is usually achieved quite simply by the additionintervention is possible.
of oral sodium bicarbonate at a dose of 1.0–4.0 g daily,Once patients are referred to a predialysis clinic, it is
provided sodium and fluid balance are satisfactory.possible to identify those at high risk of skeletal prob-
Correction of hyperphosphatemia may initially belems, in particular those with “high-risk skeletons” who
achieved by dietary modification alone, but as renal fail-have had significant exposure to oral steroids, either as
ure progresses, it will require the addition of oral phos-treatment following renal transplantation or as treatment
phorus binders taken with meals. Allowing an appropri-of their primary renal condition. Such patients would
ately trained dietician to prescribe, monitor, and alterinclude those with a history of previous fracture, signifi-
the calcium carbonate dosage within strictly defined guide-cant hypocalcemia, and/or immobility for any reason, as
lines while also advising on dietary protein and phos-well as elderly males and postmenopausal females. These
phate intake may permit even tighter control of serumgroups should be considered for bone mass measurement
phosphorus than is otherwise achievable. Phosphorusby dual X-ray absorptiometry (DEXA) and receive ap-
and calcium control should be such that a calcium 3propriate treatment for any osteopenia or osteoporosis.
phosphorus product of less than 5.5 mm2 (70 mg2/dl2) is
maintained at all times.
EARLY INTERVENTION Parathyroid hormone levels should be routinely moni-
tored every three months, while bearing in mind thatThe principles of divalent ion management are not
substantially different in predialysis patients from those the ideal level for PTH in predialysis patients has not
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Table 2. Suggested ranges for serum PTH in relation to glomerular screening for osteoporosis should be performed. Correc-
filtration rate
tion of hypocalcemia, acidosis, hyperphosphatemia and
GFR PTH rising PTH levels should be achieved quickly, while not
.50 ml/min Upper limit of normal neglecting the numerous other aspects of predialysis
20–50 ml/min 1.0–1.5 3 upper limit normal management. Intervention with oral calcitriol therapy is
,20 ml/min 1.5–2.0 3 upper limit normal
frequently necessary, and also requires careful monitor-On dialysis 2.0–3.0 3 upper limit normal
ing and supervision.GFR, glomerular filtration rate
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